Podcasts about obstetrics and gynecology

Scared? Got Questions about the continued assault on your reproductive rights? THE FBK LINES ARE OPEN! Just call or text (201) 574-7402, leave your questions or concerns, and Lizz and Moji will pick a few to address on the pod! What's going down in abobo town this week? Lizz and Moji gotchu and are reminding everyone to HOLD THE APPLAUSE – Yes, Trump's DOJ just asked to dismiss a lawsuit aiming to restrict mifepristone access, but nope, it's not the feminist victory you think it is. Your Buzzkills break down why the anti-abortion playbook is still in full swing. OH, and Missouri voters CLEARLY said yes to abortion rights in 2024, but what's conservative lawmakers latest stunt in their obsession to undo it? Tune in for the snark, the facts, and the side-eye all of this week's trash anti-abobo news deserves. GUEST ROLL CALL!Comic and indie musician Charlene Kaye, aka the funniest punk we know, drops by to yap about her solo show, Tiger Daughter, the joy she derives from creating male tears in Guitar Center, AND her new all-female Radiohead tribute band, LABIAHEAD. Yes, you heard us right – LABIAHEAD. PLUS! The incredible Dr. Karenne Fru, an Atlanta-based OBGYN and fertility expert, is in the house to talk about the intersections of IVF and abortion care because Reproductive Justice means fighting for ALL reproductive options! Times are heavy, but knowledge is power, y'all. We gotchu.  OPERATION SAVE ABORTION: You can still join the 10,000+ womb warriors fighting the patriarchy by listening to our OpSave pod series and Mifepristone Panel by clicking HERE for episodes, your toolkit, marching orders, and more. HOSTS:Lizz Winstead IG: @LizzWinstead Bluesky: @LizzWinstead.bsky.socialMoji Alawode-El IG: @Mojilocks Bluesky: @Mojilocks.bsky.social SPECIAL GUESTS:Dr. Karenne Fu IG: @munafertilityCharlene Kaye IG: @charlenekaye TikTok: @itscharlenekaye GUEST LINKS:Muna Fertility WebsiteSisterSongSPARK Reproductive Justice NOW Morehouse School of MedicineFind Your Legislatures at ResolveCharlene Kaye's WebsiteNYC 5/17: See Labiahead LIVE at Nublu! TICKETS: Charlene's "Tiger Daughter" TOUR NEWS DUMP:Missouri's Voters Restored Abortion Rights. Their Leaders Are Trying to Overrule Them.8-Foot Anti-abortion Statue Proposed for Texas Capitol GroundsPro-life Kelsey Grammer Reveals Ex Aborted Their Son, Calls Out Doctors Who've ‘Executed Generations'Trump Will Defend Biden's Abortion Pill Rules in Texas CaseSurvey of the Public's Awareness of “Fetal Personhood” and Messaging Against ItThe Fight Over IVF in Alabama Isn't Over EPISODE LINKS:ADOPT-A-CLINIC AMAZON WISHLIST: Potomac Family Planning - Hillcrest ClinicTICKETS 5/30: Genital Panic With Cindy Lawson & Quatro in Minneapolis6 DEGREES: Agatha Christie, Who Died in 1976, Will See You in ClassBUY AAF MERCH!Operation Save AbortionSIGN: Repeal the Comstock ActEMAIL your abobo questions to The Feminist BuzzkillsAAF's Abortion-Themed Rage Playlist SHOULD I BE SCARED? Text or call us with the abortion news that is scaring you: (201) 574-7402 FOLLOW US:Listen to us ~ FBK Podcast Instagram ~ @AbortionFrontBluesky ~ @AbortionFrontTikTok ~ @AbortionFrontFacebook ~ @AbortionFrontYouTube ~ @AbortionAccessFrontTALK TO THE CHARLEY BOT FOR ABOBO OPTIONS & RESOURCES HERE!PATREON HERE! Support our work, get exclusive merch and more! DONATE TO AAF HERE!ACTIVIST CALENDAR HERE!VOLUNTEER WITH US HERE!ADOPT-A-CLINIC HERE!EXPOSE FAKE CLINICS HERE!GET ABOBO PILLS FROM PLAN C PILLS HERE!When BS is poppin', we pop off!

CME credits: 1.00 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/current-management-strategies-for-fnait/32278/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother's risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

CME credits: 1.00 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/fetalneonatal-alloimmune-thrombocytopenia-fnait-the-platelet-equivalent-of-rh-disease/32275/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother's risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

CME credits: 1.00 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/classificationsuspecting-a-diagnosis-of-fnaitnait/32276/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother's risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

CME credits: 1.00 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/current-diagnostic-signs-symptoms-and-lab-tests-for-fnait/32277/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother's risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

CME credits: 1.00 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-alloimmune-disorders-of-pregnancy/32274/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother's risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

CME credits: 1.00 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-the-next-pregnancy-in-patients-with-an-fnait-affected-first-child/32279/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother's risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

CME credits: 1.00 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/neonatal-fcrn-inhibition-a-new-pathway-for-addressing-the-alloimmune-disorders-of-pregnancy/32281/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother's risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

CME credits: 1.00 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/nipocalimab-an-fcrn-inhibitor-and-its-role-in-treating-hdfn/32282/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother's risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

CME credits: 1.00 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/key-patient-counseling-issues-surrounding-fnait-and-its-risk-in-subsequent-pregnancies/32283/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother's risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

CME credits: 1.00 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/screening-for-fnait-anticipating-hpa-1a-incompatibility/32280/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother's risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

CME credits: 0.25 Valid until: 06-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-weight-of-recurrence-navigating-multidisciplinary-care-planning-in-recurringmetastatic-cervical-cancer/29168/ In recent years, the treatment landscape for recurrent or metastatic cervical cancer has undergone significant shifts with FDA approvals of first-line pembrolizumab plus platinum-doublet with or without bevacizumab and second-line tisotumab vedotin. The introduction of frontline immune checkpoint blockade also added to the challenges faced by clinicians as they choose optimal regimens for their patients. In this online CME activity, Dr. Coleman and Dr. Slomovitz offer strategies for treatment selection and sequencing with immune checkpoint inhibitors and antibody-drug conjugates for relapsed cervical cancer. Tune in to hear their expert perspectives on biomarker testing, clinical trial evidence, and multidisciplinary management of adverse events associated with these therapies to make sure your patients are getting the most out of these advances. =

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/conversations-with-patients-about-ptsd-screening-and-referral/28623/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/prevalence-and-burden-of-ptsd-in-women-focus-on-factors-that-affect-patient-presentation-such-as-race-risk-factors-stigma-and-other-drivers/28620/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/role-of-pcp-ob-gyn-with-women-at-risk-for-ptsd-recognition-screening-and-referral/28621/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/proactively-uncovering-potential-traumatic-experiences-linked-to-patient-psychiatric-symptoms-in-women/28622/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/profile-and-role-of-emerging-treatment-options-moa-safety-and-efficacy-and-identifying-the-patients-who-may-benefit/28627/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/inconsistent-outcomes-how-ignoring-guidelines-leads-to-unpredictable-results/28624/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/limitations-of-current-treatments-fda-approved-and-off-label-approaches/28625/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/pathophysiology-and-pharmacologic-rationale-of-emerging-agents-for-the-treatment-of-ptsd/28626/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/modeling-activity-quality-conversations-with-patients-about-suboptimal-management-of-ptsd-symptoms-and-emerging-treatment-options/28647/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/setting-the-stage-unmet-needs-in-the-treatment-of-women-with-ptsd/28618/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

Northwell Health has appointed Kevin Holcomb, MD, as chair of the Department of Obstetrics and Gynecology at North Shore University Hospital in Manhasset, Long Island Jewish Medical Center in New Hyde Park, and The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in Uniondale. Read the full article in Northwell's newsroom. 

CME credits: 0.50 Valid until: 09-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/case-in-point-the-use-of-gnrh-antagonists-pre-andor-post-surgery-and-the-potential-consequences-of-repeat-surgery/24400/ While both medical therapy and surgery often play a role in a woman's journey with endometriosis, it is less clear how to best sequence these approaches to optimize a patient's outcomes. Under what circumstances should you consider using a GnRH antagonist either before or after conservative surgery? Join Drs. Lee Shulman, Ayman Al-Hendy, and James Simon as they provide their collective thoughts on how best to sequence a GnRH antagonist with conservative surgery when managing endometriosis.=

CME credits: 0.50 Valid until: 09-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/pain-points-weighing-the-benefits-and-drawbacks-of-the-gnrh-antagonists-throughout-the-endometriosis-treatment-journey/24399/ GnRH antagonists have emerged as a viable first-line (or subsequent-line) medical therapy for the management of endometriosis. They have proven to be effective and safe, and their use avoids the flare response observed with GnRH agonists. Join Drs. Lee Shulman, Ayman Al-Hendy, and Sawsan As-Sanie as they discuss the estrogen threshold hypothesis from the perspective of GnRH antagonists and delve into clinical data supporting the use of GnRH antagonists in the medical management of endometriosis.=

CME credits: 0.25 Valid until: 09-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-centric-tools-to-support-shared-decision-making-diagnosing-and-assessing-endometriosis/24398/ The use of validated patient questionnaires, notably the SF-36 and EHP-30 scales, can greatly hasten the suspicion for an endometriosis diagnosis. Coupled with shared decision-making, or SDM, this patient-centered process can help ensure therapeutic adherence. Join Drs. Lee Shulman, Melissa Simon, and Linda Bradley as they discuss how to utilize the SF-36 and EHP-30 questionnaires in clinical practice and explore strategies to facilitate patient-healthcare provider discussions to improve overall short- and long-term patient outcomes.=

CME credits: 0.50 Valid until: 09-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/creating-a-practice-environment-that-enhances-healthcare-equality-for-all-patients/24397/ Both provider- and patient-related healthcare disparities exist in the diagnosis and management of endometriosis. Many disparities derive from incorrect historical biases, while others are associated with social determinants of health, or SDOH. Join Drs. Lee Shulman, Linda Bradley, and Melissa Simon as they address these issues to help facilitate a patient-centered practice environment for all patients.=

CME credits: 0.25 Valid until: 09-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-impact-of-early-diagnosis-in-improving-patient-outcomes-in-endometriosis-physical-and-psychosocial-consequences/24396/ Endometriosis is often called a public health crisis for women. The delay in diagnosis can be greater than 10 years, during which time women suffer many physical and psychosocial issues that negatively impact their quality of life. Join Drs. Lee Shulman, Sawsan As-Sanie, and Linda Bradley as they identify strategies to overcome the diagnostic delay and its associated consequences.=

CME credits: 0.25 Valid until: 08-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/innovations-in-the-management-of-hemolytic-disease-of-the-fetus-and-newborn-the-role-of-the-neonatal-fc-receptor-fcrn-pathway/16045/ Hemolytic disease of the fetus and newborn (HDFN) is an alloimmune disorder between the mother and fetus, one with significant risk for dire health consequences for both. Fortunately, a better understanding of the neonatal Fc receptor (FcRn) pathway along with the emergence of an inhibitor of this pathway has brought with it an opportunity to greatly reduce the potential harm associated with HDFN. Join us as Drs. Kenneth Moise and Kara Markham discuss the pathophysiology of HDFN and present key clinical data that may change the landscape of medical intervention for HDFN.=

CME credits: 0.25 Valid until: 29-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/consensus-recommendations-for-use-of-p16ki67-dual-staining-cytology-in-the-management-of-individuals-testing-positive-for-hpv/14675/ More effective triage tests are essential to improving cervical cancer risk-stratification and thus reducing the potential for unnecessary colposcopies. Enduring consensus cervical cancer screening recommendations, published in 2024, describe specific-use algorithms for p16/Ki-67 dual-staining cytology as an effective triage test, and also offer insight on how this test can best fit into clinical practice. Join Drs. Warner Huh and Kimberly Levinson as they first establish the rationale for using p16/Ki-67 dual-staining cytology and then break down the most salient algorithms for its use as offered in the recent recommendations.=

CME credits: 1.00 Valid until: 19-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-adc-related-pulmonary-and-cardiac-aes-in-nsclc/18167/ "Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

CME credits: 1.00 Valid until: 19-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-pulmonary-and-cardiac-adverse-events-related-to-adc-therapy-in-breast-cancer/18163/ "Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

CME credits: 1.00 Valid until: 19-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/risk-reduction-and-management-protocols-for-gastrointestinal-adverse-events-with-adc-therapy-in-breast-cancer/18164/ "Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

CME credits: 1.00 Valid until: 19-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/hematologic-adverse-events-with-adcs-in-breast-cancer-optimal-management-strategies/18165/ "Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

CME credits: 1.00 Valid until: 19-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/adcs-on-the-horizon-for-breast-cancer-managing-treatment-emergent-toxicities/18166/ "Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

CME credits: 1.00 Valid until: 19-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/optimal-management-of-adc-related-gastrointestinal-aes-in-nsclc/18168/ "Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

CME credits: 1.00 Valid until: 19-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/adc-related-hematologic-adverse-events/18169/ "Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

CME credits: 1.00 Valid until: 19-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-adc-therapies-for-nsclc-anticipating-aes-reported-in-clinical-trials/18170/ "Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

CME credits: 1.00 Valid until: 19-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/adcs-in-gynecologic-cancers-managing-pulmonary-and-cardiac-teaes/18171/ "Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

CME credits: 1.00 Valid until: 19-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/gastrointestinal-and-hematologic-teaes-related-to-adc-therapy-in-gynecologic-cancers/18172/ "Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

CME credits: 0.25 Valid until: 13-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-centric-approaches-to-managing-migraines-in-the-female-patient/16281/ Half of the women in the US with migraine are never diagnosed. Of those who are, the journey to effective treatment may last a decade or longer. But newer and more effective targeted treatments are beginning to make a difference. Join Drs. Jessica Ailani and Dawn Buse as they discuss a novel approach to managing migraine and interview a patient whose migraine journey is unfortunately one traversed by many women.=

CME credits: 0.25 Valid until: 13-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/migraine-clinical-approaches-and-a-patients-perspective/16281/ Half of the women in the US with migraine are never diagnosed. Of those who are, the journey to effective treatment may last a decade or longer. But newer and more effective targeted treatments are beginning to make a difference. Join Drs. Jessica Ailani and Dawn Buse as they discuss a novel approach to managing migraine and interview a patient whose migraine journey is unfortunately one traversed by many women.=

CME credits: 1.00 Valid until: 15-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/taking-the-patient-centered-approach-to-mycophenolate-risk-mitigation-mycophenolate-risk-mitigation/16628/ Explore this video roundtable featuring an interdisciplinary panel of experts discussing a woman's journey with mycophenolate therapy and strategies to approach risk mitigation. Learn more about how to provide critical education on the risks of mycophenolate, the importance of effective contraception, and navigating family planning.=

CME credits: 0.50 Valid until: 05-12-2024 Claim your CME credit at https://reachmd.com/programs/cme/postpartum-depression-a-significant-burden-and-a-novel-approach-to-treatment/15685/ The recent development and approval of two neuroactive steroids is likely to change the treatment paradigm for moderate to severe postpartum depression (PPD). These agents have a quick onset and function as GABAA positive allosteric modulators. Join Drs. Shulman and Deligiannidis as they address the burdens and impacts of PPD on mothers, babies, and partners, and deep dive into the pathophysiologic role and clinical findings associated with the use of neuroactive steroids in the management of PPD. =

Listen to our interview with Dr. Kacey Hamilton, the author of "Racial and Gender Representation Trends among National Obstetrics and Gynecology Society Leadership". In this episode, we discuss the trends among national society leadership demographics and look for future directions that may help improve representation in the profession. See below for publication details and be sure to join discussion on this topic through our social media platforms.Publication details:Published August 07, 2023Full text linkConnect with the JMIG Social Media Team!X: @AAGLJMIGInstagram: @AAGLJMIGFacebook: AAGLJMIG

In this episode of Label Free Podcast, host Deanna Radulescu sits down with Dr. Nathan Riley, a board certified OBGYN and founder of Beloved Holistics. Dr. Nathan shares his inspiring journey of following his purpose and offering resources for a better birthing experience and overall health. Tune in to learn more about the Born Free Method. To learn more or to connect with Dr. Nathan Riley, head to the links ⬇️:https://www.belovedholistics.comhttps://www.instagram.com/nathanrileyobgyn/00:02:40 Empower women through holistic care.00:09:21 Doctors need more holistic training.00:09:43 Incentivizing critical thinking in education.00:14:37 Addressing root causes of infertility.00:20:09 Comprehensive pregnancy education program.00:24:03 Follow your purpose, live label-free.This episode is brought to you by Supapass: For 10 years we've enabled entrepreneurs & content makers to afford the type of technology that previously only big tech platforms like Netflix or Spotify could provide to audiences ...on your own website and app!No coding, tech or design expertise needed. We empower you to keep 100% of your money, share your content on the best technology, and own the relationship with your customers.‍Grow your business, without it costing the earth. Use the code: LFG20 for 20% off at the link ⬇️:https://www.supapass.comAs always thank you for the support, to contact me directly follow the link below:https://www.labelfreepodcast.com​ Stay Healthy, Stay Ready- Deanna Marie Radulescu#podcastguest #labelfreepodcast #supapass 

  Modern Ways of Finding Out Your Baby's Gender: A Sneak Peek into the Womb Discovering the gender of your baby is an exciting milestone for expectant parents. With advances in technology, there are now several ways to determine the gender of your unborn child with remarkable accuracy. There are several ways not to determine the gender of your baby which differs much more than a few decades ago.  Ultrasound Ultrasound is the most common and widely used method to find out a baby's gender. Typically performed between 18 and 22 weeks of pregnancy, this non-invasive procedure uses sound waves to produce images of the baby in the womb. A skilled sonographer can identify the baby's gender by analyzing the images. The accuracy of ultrasound in gender determination is quite high, ranging from 95% to 99%, depending on the position of the baby and the expertise of the sonographer. Non-Invasive Prenatal Testing (NIPT) Another popular method is Non-Invasive Prenatal Testing (NIPT). This advanced screening test is performed as early as 10 weeks into the pregnancy, and it uses a blood sample from the mother to analyze the baby's DNA. NIPT is primarily used to screen for genetic conditions such as Down syndrome, but it can also determine the baby's gender with over 99% accuracy. Although NIPT is highly accurate, it is not typically performed solely for gender determination due to the higher cost compared to ultrasound. At-Home Gender Prediction Kits For parents seeking a more affordable and convenient option, at-home gender prediction kits have gained popularity. These kits use a small sample of the mother's urine to predict the baby's gender based on hormone levels. While the accuracy of these kits varies, most claim to have an accuracy rate of about 80-90%. It's important to note that at-home kits are not as reliable as ultrasound or NIPT, and the results should be taken with a grain of salt. Gender Reveal Parties Once parents have discovered the gender of their baby, many choose to share the news with friends and family in a creative way. Gender reveal parties have become a popular trend, with couples using various methods to disclose the big news, such as cutting into a cake with colored filling, popping balloons filled with colored confetti, or setting off colored smoke bombs. These parties not only make for an exciting way to reveal the baby's gender but also create lasting memories for everyone involved.   Our practice can be found  at www.maternalresources.org Reach out to us at (201) 487-8600   As always, we'd love to hear from you! Connect with us on our website at www.truebirthpodcast.com or send us an email at info@maternalresources.org     Remember to subscribe wherever you listen and considering leaving us some feedback at info@maternalresoruces.org or writieng a review.  Our Social Channels are as follows Twitter: https://twitter.com/integrativeobYouTube: https://www.youtube.com/maternalresources IG: https://www.instagram.com/integrativeobgyn/ Facebook: https://www.facebook.com/IntegrativeOB https://www.truebirthpodcast.com

Join Drs Russo and Nguyen for a discussion of the current status and history of male contraception, including research published in the journal. Relevant articles: Post-abortion contraception, an opportunity for male partners Online community queries on hormonal male contraception Male contraception is coming: Who do men want to prescribe their birth control? Medical mistrust as a barrier to male contraception for Black American men in Los Angeles, CA Access to male sexual and reproductive health services in publicly funded California clinics in 2018 Acceptability of the oral hormonal male contraceptive prototype, 11β-methyl-19-nortestosterone dodecylcarbonate (11β-MNTDC), in a 28-day placebo-controlled trial Acceptability of oral dimethandrolone undecanoate in a 28-day placebo-controlled trial of a hormonal male contraceptive prototype

This episode features Dr. Ashanda Saint Jean, Chair, Obstetrics and Gynecology at Health Alliance Hospitals, Westchester Medical Center, a member of WMCHealth. Here, she discusses her background, her focus on access and health equity, telehealth bridging the access gap for rural health, and much more.

This episode features Dr. Steven E. Lipshultz, A. Conger Goodyear Professor and Chair, Department of Pediatrics and Voluntary Clinical Professor of Obstetrics and Gynecology, University at Buffalo Jacobs School of Medicine and Biomedical Sciences;Pediatric Chief-of-Service, Kaleida Health; Medical Director of Pediatric Services Business Development, John R. Oishei Children's Hospital; Consultant, Roswell Park Comprehensive Cancer Center; and President/CEO UBMD Pediatrics Medical Group. Here, he speaks about his multiple professional roles, his top priorities, his focus on prevention & implementation research, and more.